Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer focuses on core products

This article was originally published in The Tan Sheet

Executive Summary

Bayer will retain rights to its Factor VIII hemophilia treatment Kogenate under an agreement to spin off its plasma products business to NPS Biotherapeutics. The divestiture is part of Bayer's effort to restructure itself into a mid-sized pharma company focused on oncology, OTCs and blood products. Under the $590 mil. agreement, Bayer will receive cash, a 10% equity in NPS, retention of selected capital items and contingent payments of up to $60 mil.; the deal is expected to close in the first half of 2005. Kogenate represents approximately half of Bayer's plasma products business, which also includes Polyglobin, Gamimune, Gamunex and Prolastin. NPS is a newly formed corporation controlled by venture capital firms Cerberus Capital Management and Ampersand Ventures...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS097674

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel